Back to News
Market Impact: 0.18
Barclays Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Barclays initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNZZ) on September 25, 2026, with an Overweight recommendation. The positive analyst initiation may support investor interest in the biotech-linked security, though the article provides no price target, valuation rationale, or financial projections.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
BCS0.10
LGND0.45
More News
- Humana surges: Barclays bets big on Medicare star ratings rebound
- Top Wall Street Forecasters Revamp Levi Strauss Expectations Ahead Of Q3 Earnings
- PepsiCo Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Independent Research Firms: A Publishing System
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More